Colloidal systems for CNS drug delivery

Progress in Brain Research

Volumn 180, Issue C, 2009, Pages 35-69

  Costantino, Luca ^a   Tosi, Giovanni ^a   Ruozi, Barbara ^a   Bondioli, Lucia ^a   Vandelli, Maria Angela ^a   Forni, Flavio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Blood brain barrier; Central nervous system; Drug delivery; Liposomes; Nanoparticles

Indexed keywords

NANOPARTICLE;

ANIMAL; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BRAIN; COLLOID; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PHYSIOLOGY; REVIEW; TIME; VASCULARIZATION;

ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN; COLLOIDS; DRUG DELIVERY SYSTEMS; HUMANS; METABOLIC CLEARANCE RATE; NANOPARTICLES; TIME;

EID: 77953383355     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)80003-9     Document Type: Article

References (174)

1. Allemann, E., Leroux, J. C., Gurny, R., & Doelker, E. (1993). In vitro extended release properties of drug-loaded poly(D, L-lactic acid) nanoparticles produced by a salting-out procedure. Pharmaceutical Research, 10, 1732-1737.
2. Alyautdin, R. N., Petrov, V. E., Langer, K., Berthold, A., Kharkevich, D. A., & Kreuter, J. (1997). Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharmaceutical Research, 14, 325-328.
3. Ambruosi, A., Gelperina, S., Khalansky, A., Tanski, S., Theisen, A., & Kreuter, J. (2006). Influence of surfactants, polymer and doxorubicin loading on the antitumor effect of poly (butyl cyanoacrylate) nanoparticles in a rat glioma model. Journal of Microencapsulation, 23, 582-592.
4. 14C]-poly(butylcyanoacrylate) nanoparticles after intravenous administration to glioblastomabearing rats. Journal of Drug Targeting, 14, 97-105.
5. Ambruosi, A., Yamamoto, H., & Kreuter, J. (2005). Body distribution of polysorbate 80 and doxorubicin-loaded [14C] poly(butyl cyanoacrylate) nanoparticles after i. v. administration in rats. Journal of Drug Targeting, 13, 535-542.
6. Anderson, K. E., Eliot, L. A., Stevenson, B. R., & Rogers, J. A. (2001). Formulation and evaluation of a folic acid receptor targeted oral vancomycin liposomal dosage form. Pharmaceutical Research, 18, 316-322.
7. Bangham, A. D. (1968). Membrane model with phospholipids. Progress in Biophysics and Molecular Biology. 18, 29-30.
8. Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology, 13, 238-252.
9. Batrakova, E. V., & Kabanov, A. V. (2008). Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. Journal of Controlled Release, 130, 98-106.
10. Bawa, R. (2008). Nanoparticle-based therapeutics in humans: A survey. Nanotechnology Law and Business, 5, 135-155.
11. 14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials, 13, 1093-1102.
12. Berger, N., Sachse, A., Bender, J., Schubert, R., & Brandl, M. (2001). Filter extrusion of liposomes using different devices: Comparison of liposome size, encapsulation efficiency, and process characteristics. International Journal of Pharmaceutics, 223, 55-68.
13. Bickel, U., Yoshikawa, T., & Pardridge, W. M. (2001). Delivery of peptides through the blood brain barrier. Advanced Drug Delivery Reviews, 46, 247-279.
14. Bolotin, E. M., Cohen, R., Bar, L. K., Emanuel, S. N., Lasic, D. D., & Barenholz, Y. (1994). Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes. Journal of Liposome Research, 4, 455-479.
15. Brigger, I., Morizet, J., Aubert, G., Chacun, H., Terrier-Lacombe, M. J., Couvreur, P., et al. (2002). Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. Journal of Pharmacology and Experimental Therapeutics, 303, 928-936.
16. Brigger, I., Morizet, J., Laudani, L., Aubert, G., Appel, M., Velasco, V., et al. (2004). Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopicmurine brain tumor model. Journal of Controlled Release, 100, 29-40.
17. Calvo, P., Gouritin, B., Chacun, H., Desmaele, D., D'Angelo, J., Noel, J. P., et al. (2001). Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharmaceutical Research, 18, 1157-1166.
18. Casy, A. F., & Parfitt, R. T. (1986). Opioid analgesics. Chemistry and receptors. New York: Plenum
19. Champion, J. A., Katare, Y. K., & Mitragotri, S. (2007). Particle shape: A new design parameter for micro-and nanoscale drug delivery carriers. Journal of Controlled Release, 121, 3-9.
20. Chellat, F., Merhi, Y., Moreau, A., & Yahia, L. H. (2005). Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials, 26, 7260-7275.
21. Chon, A., Cullis, P. R., & Devine, D. V. (1991). The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. Journal of Immunology, 146, 4234-4241.
22. Cortesi, R., Esposito, E., Menegatti, E., Gambari, R., & Nastruzzi, C. (1996). Effect of cationic liposomes composition on in vitro cytotoxicity and protective effect on carried DNA. International Journal of Pharmaceutics, 139, 69-78.
23. Costantino, L., Gandolfi, F., Tosi, G., Rivasi, F., Vandelli, M. A., & Forni, F. (2005). Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. Journal of Controlled Release, 108, 84-96.
24. de Boer, A. G., van der Sandt, I. C.J., & Gaillard, P. J. (2003). The role of drug transporters at the blood-brain barrier. Annual Review of Pharmacology and Toxicology, 43, 629-656.
25. Discher, B. M., Won, J. J., Ege, D. S., Lee, J., Bates, F. S., Discher, D. E., et al. (1999). Polymersomes: Tough vesicles made from diblock copolymers. Science, 284, 1143-1146.
26. Discher, D. E., & Eisenberg, A. (2002). Poliymer vesicles. Science, 297, 967-973.
27. Dong, Y., & Feng, S. S. (2004). Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials, 25, 2843-2849.
28. Eavarone, D.A., Yu, X.,&Bellamkonda, R. V. (2000). Targeted drug delivery to C6 glioma by transferring-coupled liposomes. Journal of Biomedical Materials Research, 51, 10-14.
29. Farhood, H., Bottega, R., Epand, R. M., & Huang, L. (1992). Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. Biochimica et Biophysica ACTA, 1111, 239-246.
30. Fenart, L., Casanova, A., Dehouck, B., Duhem, C., Slupek, S., Cecchelli, R., et al. (1999). Evaluation of the effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of blood brain barrier. Journal of Pharmacology and Experimental Therapeutics, 291, 1017-1022.
31. Feng, S. S., Mu, L., Win, K. Y., & Huang, G. (2004). Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Current Medicinal Chemistry, 11, 413-424.
32. Fernandez-Urrusuno, R., Fattal, E., Feger, J., Couvreur, P., & Thérond, P. (1997). Evaluation of hepatic antioxidant systems after intravenous administration of polymeric nanoparticles. Biomaterials, 18, 511-517.
33. Fernandez-Urrusuno, R., Fattal, E., Porquet, D., Feger, J., & Couvreur, P. (1995). Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicology and Applied Pharmacology, 130, 272-279.
34. Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N., & Benita, S. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. International Journal of Pharmaceutics, 55, R1-R4.
35. Filion, M. C., & Phillips, N. C. (1997). Anti-inflammatory activity of cationic lipids. British Journal of Pharmacology, 122, 551-557.
36. Fishbein, I., Chorny, M., Rabinovich, L., Banai, S., & Gati, I. (2000). Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. Journal of Controlled Release, 65, 221-229.
37. Friden, P. M., Walus, L. R., Musso, G. F., Taylor, M. A., Malfroy, B., & Starzyk, R. M. (1991). Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood brain barrier. Proceedings of the National Academy of Sciences of the United States of America, 88, 4771-4775.
38. Friese, A., Seiller, E., Quack, G., Lorenz, B., & Kreuter, J. (2000). Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. European Journal of Pharmaceutics and Biopharmaceutics, 49, 103-109.
39. Garcia-Garcia, E., Andrieux, K., Gil, S., & Couvreur, P. (2005). Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain? International Journal of Pharmaceutics, 298, 274-292.
40. Garcia-Garcia, E., Gil, S., Andrieux, K., Desmaele, D., & Nicolas, V. (2005). A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cellular and Molecular Life Science, 62, 1-9.
41. Gaspar, R., Préat, V., Opperdoes, F. R., & Roland, M. (1992). Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: Activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharmaceutical Research, 9, 782-787.
42. Gaumet, M., Gurny, R., & Delie, F. (2007). Fluorescent biodegradable PLGA particles with narrow size distributions: Preparation by means of selective centrifugation. International Journal of Pharmaceutics, 342, 222-230.
43. Gaumet, M., Vargas, A., Gurny, R., & Delie, F. (2008). Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. European Journal of Pharmaceutics and Biopharmaceutics, 69, 1-9.
44. Gelperina, S. E., Khalansky, A. S., Skidan, I. N., Smirnova, Z. S., Bobruskin, A. I., Severin, S. E., et al. (2002). Toxicological studies of doxorubicin bound to polysorbate 80-coated polybutylcyanoacrylate nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicology Letters, 126, 131-141.
45. Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., et al. (2007). Shape effects of filaments versus spherical particles in flow and drug delivery. Nature Nanotechnology, 2, 249-255.
46. Gessner, A., Olbrich, C., Schroeder, W., Kaiser, O., & Muller, R. H. (2001). The role of plasma proteins in brain targeting: Species dependent protein adsorption patterns on brain specific lipid drug conjugate (LDC) nanoparticles. International Journal of Pharmaceutics, 214, 87-91.
47. Gessner, A., Waicz, R., Lieske, A., Paulke, B. R., Mader, K., & Muller, R. H. (2000). Nanoparticles with decreasing surface hydrophobicities: Influence on plasma protein adsorption. International Journal of Pharmaceutics, 196, 245-249.
48. Gipps, E. M., Groscurth, P., Kreuter, J., & Speiser, P. P. (1987). The effects of polyalkylcyanoacrylate nanoparticles on human normal and malignant mesenchymal cells in vitro, International Journal of Pharmaceutics, 40, 23-31.
49. Gonatas, N. K., Stieber, A., Hickey, W. F., Herbert, S. H., & Gonatas, J. O. (1984). Endosomes and Golgi vesicles in adsorptive and fluid phase endocytosis. Journal of Cell Biology, 99, 1379-1390.
50. Grislain, L., Couvreur, P., Lenaerts, V., Roland, M., Deprez-Decampeneere, D., Speiser, P., et al. (1983). Pharmacokinetics and distribution of a biodegradable drug-carrier. International Journal of Pharmaceutics, 15, 335-345.
51. Gulyaev, A. E., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., & Kreuter, J. (1999). Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceutical Research, 16, 1564-1569.
52. Harris, J. M., & Chess, R. B. (2003). Effect of PEGylation on pharmaceuticals. Nature Reviews Drug Discovery, 2, 214-221.
53. Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008). Protein nanoparticles as drug carriers in clinical medicine. Advanced Drug Delivery Reviews, 60, 876-885.
54. Hongtao, L. V., Zhang, S., Wang, B., Cui, S., & Yanc, J. (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. Journal of Controlled Release, 114, 100-109.
55. Horisawa, E., Hirota, T., Kawazoe, S., Yamada, J., Yamamoto, H., Takeuchi, H., et al. (2002). Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharmaceutical Research, 19, 403-410.
56. Huang, C. Y., & Lee, Y. D. (2006). Core-shell type of nanoparticles composed of poly[(n-butyl cyanoacrylate)-co-(2-octyl cyanoacrylate)] copolymers for drug delivery application: Synthesis, characterization and in vitro degradation. International Journal of Pharmaceutics, 325, 132-139.
57. Huwyler, J., Wu, D., & Pardridge, W. M. (1996). Brain drug delivery of small molecules using immunoliposomes. Proceedings of the National Academy of Sciences of the United States of America, 93, 14164-14169.
58. Huwyler, J., Yan, J., & Pardridge, W. M. (1997). Receptor mediated delivery of daunomycin using immunoliposomes: Pharmacokinetics and tissue distribution in the rat. Journal of Pharmacology and Experimental Therapeutics, 282, 1541-1546.
59. Jallouli, Y., Paillard, A., Chang, J., Sevin, E., & Betbeder, D. (2007). Influence of surface charge and inner composition of porous nanoparticles to cross the blood brain barrier in vitro. International Journal of Pharmaceutics, 344, 103-109.
60. Kabanov, A. V., & Batrakova, E. V. (2004). New technologies for drug delivery across the blood brain barrier. Current Pharmaceutical Design, 10, 1355-1363.
61. Kante, B., Couvreur, P., Dubois-Krack, G., De Meester, C., Guiot, P., Roland, M., et al. (1982). Toxicity of polyalkylcyanoacrylate nanoparticles I: Free NPs. Journal of Pharmaceutical Sciences, 72, 786-790.
62. Kattan, J., Droz, J. P., Couvreur, P., Marino, J. P., Boutan-Laroze, L. A., Rougier, P., et al. (1992). Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Investigational New Drugs, 10, 191-199.
63. Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008). Potential of solid lipid nanoparticles in brain targeting. Journal of Controlled Release, 127, 97-109.
64. Kerns, E., & Di, L. (2008). Drug-like properties: Concepts, structure design and methods (pp. 122-136). New York: Academic Press.
65. Kim, H. R., Andrieux, K., Gil, S., Taverna, M., Chacun, H., Desmaële, D., et al. (2007). Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: Role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules, 8, 793-799.
66. Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2003). In situ blood-brain barrier transport of nanoparticles. Pharmaceutical Research, 20, 1772-1778.
67. Kratzer, I., Wernig, K., Panzenboeck, U., Bernhart, E., & Reicher, H. (2007). Apolipoprotein A-I coating on protamine oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. Journal of Controlled Release, 117, 301-311.
68. Kreuter, J. (2001). Nanoparticulate systems for brain delivery of drugs. Advanced Drug Delivery Reviews, 47, 65-81.
69. Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Ivanov, A. A. (1995). Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Research, 674, 171-174.
70. Kreuter, J., Hekmatara, T., Dreis, S., Vogel, T., Gelperina, S., & Langer, K. (2007). Covalent attachment of apolipoprotein A-I and B-100 to albumin nanoparticles enables drug transport into the brain. Journal of Controlled Release, 118, 54-58.
71. Kreuter, J., Petrov, V. E., Kharkevich, D. A., & Alyautdin, R. N. (1997). Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactantcoated nanoparticles. Journal of Controlled Release, 49, 81-87.
72. Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S. E., Engelhardt, B., et al. (2003). Direct evidence that polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharmaceutical Research, 20, 409-416.
73. Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., et al. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. Journal of Drug Targeting, 10, 317-325.
74. Kubiak, C., Couvreur, P., Manil, L., & Clausse, B. (1989). Increased cytotoxicity of nanoparticle-carried adriamycin in vitro and potentiation by verapamil and amiodarone. Biomaterials, 10, 553-556.
75. Kulkarni, S. B., Betageri, G. V., & Singh, M. (1995). Factors affecting microencapsulation of drugs in liposomes. Journal of Microencapsulation, 12, 229-246.
76. Kumagai, A. K., Eisenberg, J. B., & Pardridge, W. M. (1987). Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model systemof blood brain barrier transport. Journal of Biological Chemistry, 262, 15214-15219.
77. Lappalainen, K., Jääskeläinen, I., Syrjänen, K., Urtti, A., & Syrjänen, S. (1994). Comparison of cell proliferation and toxicity assays using two liposomes. Pharmaceutical Research, 11, 1127-1131.
78. Lasch, J., Wesseig, V., & Brandl, M. (2003). Preparation of liposomes, In V. Torchilin & V. Wessing (Eds.), Liposomes: A practical approach (2nd ed., pp. 3-16). Oxford: Oxford University Press.
79. Lee, R. J., & Low, P. S. (1995). Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochimica et Biophysica ACTA, 1233, 134-144.
80. Lemarchand, C., Gref, R., Passirani, C., Garcion, E., Petri, B., Müller, R., et al. (2006). Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials, 27, 108-118.
81. Lherm, C., Müller, R. H., Puisieux, F., & Couvreur, P. (1992). Alkylcyanoacrylate drug carriers II. Cytotoxicity of cyanoacrylate nanoparticles with different alky chain length. International Journal of Pharmaceutics, 84, 13-22.
82. Li, S. (1999). Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. Journal of Biomedical Materials Research (Applied Biomaterials), 48, 342-353.
83. Liu, L., Guo, K., Lu, J., Venkatraman, S. S., Luo, D., Moochhala, S. et al. (2008). Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials, 29, 1509-1517.
84. Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. Journal of Drug Targeting, 12 (9-10), 635-641.
85. Lockman, P. R., Koziara, J., Roder, K. E., Paulson, J., Abbruscato, T. J., Mumper, R. J., et al. (2003). In vivo and in vitro assessment of baseline blood brain barrier parameters in the presence of novel nanoparticles. Pharmaceutical Research, 20, 705-713.
86. Lockman, P. R., Oyewumi, M. O., Koziara, J. M., Roder, K. E., Mumper, R. J., & Allen, D. D. (2003). Brain uptake of thiamine-coated nanoparticles. Journal of Controlled Release, 93, 271-282.
87. Lode, J., Fichtner, I., Kreuter, J., Berndt, A., Diederichs, J. E., & Reszka, R.. (2001). Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly(methylmethacrylate) nanoparticles in experimental tumor models. Pharmaceutical Research, 18, 1613-1619.
88. Lu, W., Sun, Q., Wan, J., She, Z., & Jiang, X. (2006). Cationic Albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Research, 66, 11878-11887.
89. Lu, W., Wan, J., She, Z., & Jiang, X. (2007). Bain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. Journal of Controlled Release, 118, 38-53.
90. Lu, W., Zhang, X., Tan, Y. Z., Hu, K. L., Jiang, X. G., & Fu, S. K. (2005). Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. Journal of Controlled Release, 107, 428-448.
91. Lukowski, G., Müller, R. H., Müller, B. W., & Dittgen, M. (1992). Acrylic acid copolymer nanoparticles for drug delivery: I. Characterization of the surface properties relevant for in vivo organ distribution. International Journal of Pharmaceutics, 84, 23-31.
92. Maassen, S., Fattal, E., Müller, R. H.,&Couvreur, P. (1993). Cell cultures for the assessment of toxicity and uptake of polymeric particulate drug carriers. STP Pharma Sciences, 3, 11-22.
93. Manjunath, K., & Venkateswarlu, V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. Journal of Controlled Release, 107, 215-228.
94. Maruyama, K., Takizawa, T., Yuda, T., Kennelm, S. J., Huang, L., & Iwatsuru, M. (1995). Targetability of novel immunoliposomes modified with amphipathic poly (ethylene glycol)s conjugated of their distal terminals to monoclonal antibodies. Biochimica et Biophysica ACTA, 1234, 74-80.
95. Mayer, L. D., Bally, M. B., & Cullis, P. R. (1986). Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochimica et Biophysica ACTA, 857, 123-126.
96. Menei, P., Daniel, V., Montero-Menei, C., Brouillard, M., Pouplard-Barthelaix, A., & Benoit, J. P. (1993). Biodegradation and brain tissue reaction to poly(D, L-lactide-co-glycolide) microspheres. Biomaterials, 14, 470-478.
97. Michaelis, K., Hoffmann. M. M., Dreis. S., Herbert. E., Alyautdin, R. N., Michaelis, M., et al. (2006). Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. Journal of Pharmacology and Experimental Therapeutics, 317, 1246-1253.
98. Moghimi, S. M., & Szebeni, J. (2003). Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress in Lipid Research, 42, 463-478.
99. Mora, M., Sagrista, M. L., Trombetta, D., Bonina, F. P., De Pasquale, A., & Sajia, A. (2002). Design and characterization of liposomes containing long-chain N-AcylPEs for brain delivery: Penetration of liposomes incorporating GM1 into the rat brain. Pharmaceutical Research, 19, 1430-1438.
100. Müller, R. H., Lherm, C., Herbert, J., & Couvreur, P. (1990). In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials, 11, 590-595.
101. Müller, R. H., Lherm, C., Herbort, J., Blunk, T., & Couvreur, P. (1992). Alkylcyanoacrylate drug carriers: I. Physicochemical characterization of nanoparticles with different alkyl chain length. International Journal of Pharmaceutics, 84, 1-11.
102. Nam, Y. S., Park, Y., Han, S. H., & Chang, I. S. (2002). Intracellular drug delivery using poly(D, L-lactide-co-glycolide) nanoparticles derivatized with a peptide from a transcriptional activator protein of HIV-1. Biotechnology Letters, 14, 2093-2098.
103. New, R. R.C. (1989). Preparation of liposomes. In R. R.C. New (Ed.), Liposomes. A practical approach (pp. 33-104). London: Oxford University Press.
104. Nicholas, A. P., McInnis, C., Gupta, K. B., Snow, W. W., Love, D. F., Mason, D. W., et al. (2002). The fate of biodegradable microspheres injected into rat brain. Neuroscience Letters, 323, 85-88.
105. Nuzzo, F., Sala, F., Biondi, O., Casati, A., Cestaro, B.,&DeCarli, L. (1985). Liposomes induce chromosome aberrations in human cultured cells. Experimental Cell Research, 157, 397-408.
106. Olivier, J. C. (2005). Drug transport to brain with targeted nanoparticles. NeuroRx, 2, 108-119.
107. Olivier, J. C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., & Couet, W. (1999). Indirect evidence that drug brain targeting using polysorbate-80 coated polybutylcyanoacrylate nanoparticles is relatedtotoxicity.PharmaceuticalResearch,16,1836-1842.
108. Owens, D. E., III, & Peppas, N. A. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics, 307, 93-102.
109. Pang, Z., Lu, W., Gao, H., Hu, K., Chen, J., Zhang, C., et al. (2008). Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. Journal of Controlled Release, 128, 120-127.
110. Panyam, J., Zhou, W. Z., Prabha, S., Sahoo, S. K., & Labhasetwar, V. (2002). Rapid endo-lysosomal escape of poly(D, Llactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB Journal, 16, 1217-1226.
111. Panzenboeck, U., Balasz, A., Sovic, A., Hrzenjac, A., Levak-Frank, S., Wintersperger, A., et al. (2002). ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood brain barrier constituted of porcine brain capillary endothelial cells. Journal of Biological Chemistry, 277, 42781-42789.
112. Pardridge, W. M. (1995). Vector-mediated peptide drug delivery to the brain. Advanced Drug Delivery Reviews, 15, 109-146.
113. Pardridge, W. M. (2001). Brain drug targeting: The future of brain drug development (pp. 1-370). Cambridge: Cambridge University Press.
114. Pardridge, W.M. (2002). Non-invasive gene targeting to the brain. US-Patent 6372250.
115. Parhham, M. J., & Wetzig, H. (1993). Toxicity screening of liposomes. Chemistry and Physics of Lipids, 64, 263-274.
116. Peracchia, M. T., Gref, R., Minamitake, Y., Domb, A., Lotan, N., & Langer, R. (1997). PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Investigation of their drug encapsulation and release characteristics. Journal of Controlled Release, 46, 223-231.
117. Petri, B., Bootz, A., Khalansky, A., Hekmatara, T., Muller, R., Uhl, R., et al. (2007). Chemotherapy of brain tumors using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. Journal of Controlled Release, 117, 51-58.
118. Polt, R., & Palian, M. M. (2001). Glycopeptide analgesics. Drugs Future, 26, 561-576.
119. Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002). Targeted drug delivery via the transferrin receptor mediated endocytosis pathway. Pharmacological Reviews, 54, 561-587.
120. Reddy, H. L., Sharma, R. K., Chuttani, K., Mishra, A. K., & Murthy, R. R. (2004). Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies. AAPS Journal, 6, 1-10, Article 23.
121. Roser, M., Fischer, D., & Kissel, T. (1998). Surface-modified biodegradabile albumin nano- and microspheres. II: Effect of surface charge on in vitro phagocytosis and biodistribution in rats. European Journal of Pharmaceutics and Biopharmaceutics, 46, 255-263
122. Ruozi, B., Forni, F., Battini, R., & Vandelli, M. A. (2003). Cationic liposomes for gene transfection. Journal of Drug Targeting, 11, 407-414.
123. Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. (2002). Residual polyvinyl alcohol associated with poly (image,imagelactide-co-glycolide)nanoparticles affects their physicalproperties and cellular uptake. Journal of Controlled Release, 82, 105-114.
124. Santra, S., Yang, H., Dutta, D., Stanley, J. T., Holloway, P. H., Tan, W., et al. (2004). TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. Chemical Communications, 24, 2810-2811.
125. Santra, S., Yang, H., Stanley, J. T., Holloway, P. H., Moudgil, B. M., Walter, G., et al. (2005). Rapid and effective labelling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chemical Communications, 25, 3144-3146.
126. Sauer, I., Dunay, I. R., Weisgraber, K., Bienert, M., & Dathe, M. (2005). An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochemistry, 44, 2021-2029.
127. Sauer, I., Nikolenko, H., Keller, S., Ajaj, K. A., Bienert, M., & Dathe, M. (2006). Dipalmitoylation of a cellular uptakemediating apolipoprotein E-derived peptide as a promising modification for stable anchorage in liposomal drug carriers. Biochimica et Biophysica ACTA, 1758, 552-561.
128. Saul, J. M., Annapragada, A., Natarajan, J. V., & Bellamkonda, R. V. (2003). Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. Journal of Controlled Release, 92, 49-67.
129. Schlageter, K. E., Molnar, P., Lapin, G. D., & Groothuis, D. R. (1999). Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvascular Research, 58, 312-328.
130. Schroeder, U., Schroeder, H., & Sabel, B. A. (2000). Body distribution of 3H-labelled dalargin bound to poly(butylcyanoacrylate) nanoparticles after their i.v. injection in mice. Life Sciences, 66, 495-502.
131. Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999). In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science, 285, 1569-1572.
132. Senior, J. (1987). Fate and behaviour of liposomes in vivo: A review of controlling factors. Critical Reviews in Therapeutic Drug Carrier Systems, 3, 123-193.
133. Shi, N., Boado, R. J., & Pardridge, W. M. (2001). Receptormediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharmaceutical Research, 18(8), 1091-1095.
134. Shi, N., & Pardridge, W. M. (2000). Noninvasive gene targeting to the brain. Proceedings of the National Academy of Sciences of the United States of America, 97, 7567-7572.
135. Shi, N., Zhang, Y., Zhu, C., Boado, R. J., & Pardridge, W. M. (2001). Brain specific expression of an exogenous gene after i.v. administration. Proceedings of the National Academy of Sciences of the United States of America, 98, 12754-12759.
136. Smith, Q. R. (1993). Drug delivery to the brain and the role of carrier mediated transport. In L. R. Drewes & A. L. Betz (Eds.), Frontiers in cerebral vascular biology: Transport and its regulation (pp. 83-93). New York: Plenum.
137. Sonavane, G., Tomoda, K., & Makino, K. (2008). Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids and Surfaces B: Biointerfaces, 66, 274-280.
138. Soni, V., Kohli, D. V., & Jain, S. K. (2005). Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-fluorouracil. Journal of Drug Targeting, 13, 245-250.
139. Soni, V., Kohli, D. V., & Jain, S. K. (2008). Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. Journal of Drug Targeting, 16, 73-78.
140. Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled Release, 70, 1-20.
141. Steiniger, S. C.J., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. T., Smirnova, Z. S., et al. (2004). Chemotherapy of glioblastoma in rats using doxorubicinloaded nanoparticles. International Journal of Cancer, 109, 759-767.
142. Szoka, F., & Papahadjopoulos, D. (1978). Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Academy of Sciences of the United States of America, 75, 4194-4198.
143. Tabata, Y., & Ikada, Y. (1988). Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials, 9, 356-362.
144. Takasato, Y., Rapaport, S. I., & Smith, Q. R. (1984). An in situ brain perfusion technique to study cerebrovascular transport in the rat. American Journal of Physiology, 247, M484-M493.
145. Taniguchi, K., Yamamoto, Y., Itakura, K., Miitchi, H., & Hayashi, S. J. (1988). Assessment of ocular irritability of liposomes preparations. Journal of Pharmacobio-Dynamics, 11, 607-611.
146. Thole, M., Nobmann, S., Huwyler, J., Bartmann, A., & Fricker, G. (2002). Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. Journal of Drug Targeting, 10, 337-344.
147. Tosi, G., Costantino, L., Rivasi, F., Ruozi, B., Leo, E., Vergoni, A. V., et al. (2007). Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and Rhodamine-123. Journal of Controlled Release, 122, 1-9.
148. Triguero, D., Buciak, J., & Pardridge, W. M. (1990). Capillary depletion method for quantification of blood brain barrier transport of circulating peptides and plasma proteins. Journal of Neurochemistry, 54, 1882-1888.
149. Tseng, Y. C., Tabata, Y., Hyon, S. H., & Ikada, Y. (1990). In vitro toxicity of 2-cyanoacrylate polymers by cell culture method. Journal of Biomedical Materials Research, 24, 1355-1367.
150. Ubrich, N., Bouillot, P., Pellerin, P., Hoffmann, M., & Maincent, P. (2004). Preparation and characterization of propranolol hydrochloride nanoparticles: A comparative study. Journal of Controlled Release, 97, 291-300.
151. Umezawa, F., & Eto, Y. (1988). Liposome targeting to mouse brain: Mannose as a recognition marker. Biochemical and Biophysical Research Communications, 153, 1038-1044.
152. Vajkoczy, P., & Menger, M. D. (2004). Vascular microenvironment in gliomas. Cancer Treatment and Research, 117, 249-262.
153. Vauthier, C., Dubernet, C., Fattal, E., Pinto-Alphandary, H., & Couvreur, P. (2003). Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications, Advanced Drug Delivery Reviews, 55, 519-548.
154. Vauthier, C., Labarre, D., & Ponchel, G. (2007). Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. Journal of Drug Targeting, 15, 641-663.
155. Vergoni, A. V., Tosi, G., Tacchi, R., Vandelli, M. A., Bertolini, A., Costantino, L. (in press). Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine, in press.
156. Vinogradov, S. V., Batrakova, E. V., & Kabanov, A. V. (2004). Nanogels for oligonucleotide delivery to the brain. Bioconjugate Chemistry, 15, 50-60.
157. Vinters, H. V., & Ho, H. W. (1988). Effects of isobutyl 2-cyanoacrylate polymer on cultured cells derived from murine cerebral microvessels. Toxicology. In Vitro, 2, 37-41.
158. Visser, C. C., Stefanovich, S., Voorwinden, L. H., Gaillard, P. J., Crommelin, A. J.A., Danhof, M., et al. (2004). Validation of transferrin receptor for drug delivery to brain capillary endothelial cells in vitro. Journal of Drug Targeting, 12, 145-150.
159. Visser, C. C., Stefanovic, S., Voorwinden, L. H., van Bloois, L., Gaillard, P. J., Danhof, M., et al. (2005). Targeting liposomes with protein drugs to the blood-brain barrier in vitro. European Journal of Pharmaceutical Science, 25, 299-305
160. Vonarbourg, A., Passirani, C., Saulnier, P., & Benoit, J. P. (2006). Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, 27, 4356-4373.
161. Wang, S., Lee, R. J., Cauchon, G., Gorenstein, D. G., & Low, P. S. (1995). Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol, Proceedings of the National Academy of Sciences of the United States of America, 92, 3318-3322.
162. Wei, L., Tanb, Y., Hua, K., & Jiang, X. (2005). Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier, International Journal of Pharmaceutics, 295, 247-260.
163. Weitman, S. D., Lark, R. H., Coney, L. R., Fort, D. W., Frasca, V., Zurawski, V. R., et al. (1992). Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Research, 52, 3396-3401.
164. Xiang, J. J., Tang, J. Q., Zhu, S. G., Nie, X. M., Lu, H. B., Shen, S. R., et al. (2003). IONP-PLL: A novel non-viral vector for efficient gene delivery. Journal of Gene Medicine, 5, 803-817.
165. Xiang, J. J., Zhu, S. G., & Li, G. Y. (2001). Using iron oxide nanoparticles as gene carrier. Chinese Journal of Cancer, 20, 1-6.
166. Xie, Y., Ye, L., Zhang, X., Cui, W., Lou, J., Nagai, T., et al. (2005). Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: In vitro and in vivo studies. Journal of Controlled Release, 105, 106-119.
167. Zelphati, O., & Szoka, F. C. (1996). Mechanism of oligonucleotide release from cationic liposomes. Proceedings of the National Academy of Sciences of the United States of America, 93, 11493-11498.
168. Zhang, X., Xie, J., Li, S., Wang, X., & Hou, X. (2003). The study on brain targeting of the amphotericin B liposomes. Journal of Drug Targeting, 11, 117-122.
169. Zhang, Y., Calon, F., Zhu, C., Boado, R., & Pardridge, W. M. (2003). Intravenous non-viral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in expertimental parkinsonism. Human Gene Therapy, 14, 1-12.
170. Zhang, Y., Lee, H. J., Boado, R. J., & Pardridge, W. M. (2002). Receptor-mediated delivery of an antisense gene to human brain cancer cells. Journal of Gene Medicine, 4, 183-194.
171. Zhang, Y., Schlachetzki, F., & Pardridge, W. M. (2003). Global non viral gene transfer to the primate brain following intravenous administration. Molecular Therapy, 7, 11-18.
172. Zhang, Y., Schlachetzki, F., Zhang, Y. F., Boado, R. J., & Pardridge, W. M. (2004). Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous non viral gene therapy and a brain specific promoter. Human Gene Therapy, 15, 339-350.
173. Zhang, Y., Zhang, Y. F., Bryant, J., Charles, A., Boado, R. J., & Pardridge, W. M. (2004). Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clinical Cancer Research, 10, 3667-3677.
174. Zhang, Y., Zhu, C., & Pardridge, W. M. (2002). Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Molecular Therapy, 6, 67-72.